Logo
x

Search

Subscribe Now

Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

  • May 17, 2021
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

  • September 22, 2020
Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

  • August 31, 2020
Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria

Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria

  • September 25, 2019
Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) in India

Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal H...

  • August 16, 2019
Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults

Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria i...

  • July 4, 2019
Chugai Reports the NDA Submission of Crovalimab to the MHLW for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Japan

    Chugai Reports the NDA Submission of Crovalimab to the MHLW for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Japan

    • June 14, 2023
    Samsung Bioepis Presented Results of SB12 (biosimilar, eculizumab) for the treatment of Paroxysmal Nocturnal Hemoglobinuria at EHA 2023

      Samsung Bioepis Presented Results of SB12 (biosimilar, eculizumab) for the treatment of Paroxysmal Nocturnal Hemoglobinuria at EHA...

      • June 8, 2023
      Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria

        Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobi...

        • May 30, 2023
        Novartis Presents P-III Trial (APPOINT-PNH) Results of Iptacopan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria at EBMT 2023

          Novartis Presents P-III Trial (APPOINT-PNH) Results of Iptacopan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria at EBMT...

          • April 27, 2023
          Genentech Reports P-III Study (COMMODORE 2) Results of Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

            Genentech Reports P-III Study (COMMODORE 2) Results of Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

            • February 7, 2023
            Novartis Reports P-III (APPLY-PNH) Trial Results of Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

              Novartis Reports P-III (APPLY-PNH) Trial Results of Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

              • October 25, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.